Mar 5 |
Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
|
Mar 5 |
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call Transcript
|
Mar 5 |
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
|
Mar 4 |
Avadel surges after royalty rate awarded to Jazz in patent dispute lower than requested (update)
|
Mar 4 |
Avadel Pharmaceuticals Issues Statement On Patent Litigation
|
Mar 4 |
Avadel Pharmaceuticals plc (AVDL) Q4 2023 Earnings Call Transcript
|
Mar 4 |
Avadel Pharmaceuticals GAAP EPS of -$0.32 misses by $0.07, revenue of $19.5M misses by $6.2M
|
Mar 4 |
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 4 |
Earnings Scheduled For March 4, 2024
|
Mar 1 |
Avadel Pharmaceuticals Q4 2023 Earnings Preview
|